{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-283294","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.321211+00:00","generated_at":"2026-05-16T19:47:26.867641+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eledon reports Q3 net loss $17.5M; Phase 2 BESTOW positive; raises $57.5M","bullets":["Net loss $17.5M ($0.21/shr) vs net income $77M (incl $96.4M warrant gain) in Q3 2024.","Cash & investments $93.4M at Sep 30, down from $140.2M at Dec 31, 2024.","Phase 2 BESTOW: tegoprubart showed favorable safety, eGFR ~69 at 12 months; plans Phase 3 in 2026.","Completed $57.5M public offering on Nov 13, net proceeds ~$53.6M to advance transplant programs.","Anticipates FDA guidance on Phase 3 trial design for kidney transplantation in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-283294","json":"https://secwatch.observer/filing/0001193125-25-283294.json","markdown":"https://secwatch.observer/filing/0001193125-25-283294.md","text":"https://secwatch.observer/filing/0001193125-25-283294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000119312525283294/0001193125-25-283294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000119312525283294/eldn-20251114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:47:26.867641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}